Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

Why did bitcoin price plummet recently? How could Nvidia's chip sales to China impact growth? What caused Tyson Foods to close its beef facility? Why is Marjorie Taylor Greene resigning from Congress? How did Trump and Mamdani's meeting affect NYC politics? What triggered recent volatility in the US stock market? Why did Eli Lilly reach a $1 trillion valuation?

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

benzinga.com/news/health-care/25/11/49008003/contineum-therapeutics-multiple-sclerosis-trial-disappoints-but-analyst-sees-other-assets-drivin

Contineum Therapeutics, Inc. (NASDAQ:CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS).
RRMS is the most common type of MS, characterized by unpredictable periods of new or worsening…

This story appeared on benzinga.com, 2025-11-21 16:49:05.